Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGR-542
- Development stage
- Preclinical
- Lead developer
- Metagone Biotech
01
Overview
SGR-542 (also known as Elexis SGR542 or China SGR/542) is a matrix-based therapeutic candidate being developed by Metagone Biotech in collaboration with Elexis. The product is classified under a "Matrix" modality and is designed to target the extracellular matrix (EX). While specific clinical indications are not explicitly detailed in the company's primary drug development pipeline, it is listed as a distinct project, suggesting applications in regenerative medicine, tissue engineering, or as a specialized scaffold for wound healing or ophthalmic repair. The development status is currently listed as in progress, though specific clinical phases have not been disclosed.
- Other names
- China SGR/542
Beyond the preview
Go deeper on SGR-542.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGR-542.